A Propensity Score-Adjusted Comparison of Lenalidomide plus R-CHOP Versus R-CHOP for MYC-Rearranged DLBCL Patients

被引：0
|
作者：
de Jonge, A. Vera [1 ]
van Werkhoven, Erik D. [2 ]
Dinmohamed, Avinash G. [3 ]
Nijland, Marcel [4 ,5 ]
Zwinderman, Aeilko H. [6 ]
Bossuyt, Patrick M. [7 ]
Veldhuis, Martine S. [8 ]
Rutten, Emma G. G. M. [9 ]
Mous, Rogier [10 ]
Vermaat, Joost S. P. [11 ]
Sandberg, Yorick [12 ]
de Jongh, Eva [13 ]
Bilgin, Yavuz M. [14 ]
Boersma, Rinske [15 ]
Koene, Harry R. [16 ]
Kersten, Marie Jose [17 ]
de Jong, Daphne [18 ]
Chamuleau, Martine E. D. [1 ]
机构：
[1] Vrije Univ Amsterdam, Canc Ctr Amsterdam, Amsterdam UMC, Dept Hematol, Amsterdam, Netherlands
[2] Erasmus MC, Hovon Data Ctr, Dept Hematol, Canc Inst, Rotterdam, Netherlands
[3] Netherlands Comprehens Canc Org IKNL, Dept Res & Dev, Utrecht, Netherlands
[4] Univ Med Ctr Groningen, Dept Hematol, Groningen, Netherlands
[5] Univ Groningen, Groningen, Netherlands
[6] Univ Amsterdam, Amsterdam UMC, Dept Clin Epidemiol Biostat & Bioinformat, Amsterdam, Netherlands
[7] Locat Univ Amsterdam, Dept Clin Epidemiol, Amsterdam UMC, Biostat, Amsterdam, Netherlands
[8] Locat Vrije Univ Amsterdam, Dept Hematol, Amsterdam UMC, Amsterdam, Netherlands
[9] Locat Vrije Univ Amsterdam, Dept Pathol, Amsterdam UMC, Amsterdam, Netherlands
[10] Univ Med Ctr Utrecht, Dept Hematol, Utrecht, Netherlands
[11] Leiden Univ, Dept Hematol, Med Ctr, Leiden, Netherlands
[12] Maasstad Hosp, Dept Internal Med, Rotterdam, Netherlands
[13] Albert Schweitzer Hosp, Dept Hematol, Dordrecht, Netherlands
[14] Admiraal de Ruijter Hosp, Dept Internal Med, Goes, Netherlands
[15] Amphia Hosp, Dept Internal Med, Breda, Netherlands
[16] St Antonius Hosp, Dept Hematol, Nieuwegein, Netherlands
[17] Acad Med Ctr, Dept Hematol, Amsterdam, Netherlands
[18] Vrije Univ Amsterdam, Amsterdam UMC, Dept Pathol, Canc Ctr Amsterdam, Amsterdam, Netherlands
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-163204
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2059 / 2060
页数：2
相关论文
共 50 条
  • [41] Dose-adjusted EPOCH-R plus venetoclax: a toxic bend in the road to improving R-CHOP?
    Chamuleau, Martine E. D.
    LANCET HAEMATOLOGY, 2021, 8 (11): : E781 - E783
  • [42] Randomized, phase III trial of the efficacy and safety of lenalidomide plus R-CHOP vs R-CHOP in patients with untreated ABC-type diffuse large B-cell lymphoma.
    Nowakowski, Grzegorz S.
    Chiappella, Annalisa
    Witzig, Thomas E.
    Spina, Michele
    Zhang, Lei
    Flament, Jocelyne
    Repici, Jacqueline
    Vitolo, Umberto
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [43] RANDOMIZED PHASE II STUDY OF R-CHOP PLUS ENZASTAURIN VERSUS R-CHOP IN THE FIRST-LINE TREATMENT OF PATIENTS WITH INTERMEDIATE AND HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) - PRELIMINARY ANALYSIS
    Hainsworth, J. D.
    Arrowsmith, E. R.
    Mccleod, M.
    Fayad, L. E.
    Hamid, O.
    Davis, L.
    Lin, B.
    ANNALS OF ONCOLOGY, 2011, 22 : 107 - 107
  • [44] POLARIX: A phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL.
    Tilly, Herve
    Flowers, Christopher
    Friedberg, Jonathan W.
    Herbaux, Charles
    Morschhauser, Franck
    Sehn, Laurie Helen
    Sharman, Jeff Porter
    Trneny, Marek
    Lee, Calvin
    Salles, Gilles A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [45] Characterising Tumour and Microenvironmental Responses to R-CHOP in Immunocompetent Mouse Models of DLBCL
    Maybury, Bernard D.
    Bewicke-Copley, Findlay
    Peter, Johnson
    Fitzgibbon, Jude
    Calado, Dinis Pedro
    BLOOD, 2021, 138
  • [46] Ultrasensitive MRD Profiling Predicts Outcomes in DLBCL after Frontline Therapy with Tafasitamab in Combination with Lenalidomide and R-CHOP
    Kurtz, David M.
    Hogan, Gregory J.
    Schultz, Andre
    Kopeckova, Katerina
    Kuffer, Christian
    Blair, Derek
    Wagner, Steve
    Close, Sandra
    Diehn, Maximilian
    Chabon, Jacob J.
    Alizadeh, Ash A.
    Westin, Jason
    BLOOD, 2022, 140 : 3498 - 3499
  • [47] Ibrutinib plus bortezomib plus R-CHOP for higher-risk DLBCL: Efficacy, feasibility and molecular predictors
    Denker, S.
    Bittner, A.
    Frick, M.
    Kase, J.
    Hoffmann, J.
    Trenker, C.
    Keller, U.
    Bogner, C.
    Huttmann, A.
    Duhrig, J.
    Janz, M.
    Mathas, S.
    Marks, R.
    Krohn, U.
    Bhattacharya, A.
    Na, I. -K
    Gebauer, B.
    Savic, L. J.
    Hubner, N.
    Akalin, A.
    Eils, R.
    Bullinger, L.
    Schmitt, C. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 24 - 24
  • [48] A DLBCL PATIENT ACCOMPANIED BY ITP TREATED WITH R-CHOP AND THROMBOPOIETIN RECEPTOR AGONIST
    Kurita, D.
    Hatta, Y.
    Kobayashi, Y.
    Hirabayashi, Y.
    Kiso, S.
    Kodaira, H.
    Takahashi, H.
    Miura, K.
    Nakagawa, M.
    Takeuchi, J.
    ANNALS OF ONCOLOGY, 2013, 24
  • [49] DA-R-EPOCH vs R-CHOP in DLBCL: How Do We Choose?
    Major, Ajay
    Smith, Sonali M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (11) : 698 - +
  • [50] Succeeding in Breaking the R-CHOP Ceiling in DLBCL: Learning From Negative Trials
    Goy, Andre
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (31) : 3519 - +
12345